πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
1,136

Quick answer

First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. retinal pigment epithelium transplantation

    The First People's Hospital of Lianyungang

    Dry Age-related Macular Degeneration

    phase 2 mab active

    1 trial

  2. rituximab /Dexamethasone/cyclophosphamide

    The First People's Hospital of Lianyungang

    Treatment

    phase 2 small molecule active

    1 trial

  3. sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  4. sintilimab

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  5. ssCART-19

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  6. ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Adult B-Cell

    phase 2 mab active

    1 trial

  7. surufatinib + fulvestrant + chidamide

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  8. tauroursodeoxycholic acid (TUDCA)

    The First People's Hospital of Lianyungang

    Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development

    phase 2 small molecule active

    1 trial

  9. toripalimab

    The First People's Hospital of Lianyungang

    Malignant Melanoma

    phase 2 small molecule active

    1 trial

  10. trifluridine/tipiracil combined with fufuquitinib

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. unrelated umbilical cord blood

    The First People's Hospital of Lianyungang

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  12. veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  13. 18F-FAPIBiotin

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  14. 18F-FDG

    The First People's Hospital of Lianyungang

    Multiple Myeloma and Malignant Plasma Cell Neoplasms

    phase 1 small molecule active

    1 trial

  15. 68Ga-AAZTA-NI-093

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 1 small molecule active

    1 trial

  16. 68Ga-BNU-PSMA

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 other active

    1 trial

  17. 68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI

    The First People's Hospital of Lianyungang

    177Lu-DOTA-FAPI

    phase 1 small molecule active

    1 trial

  18. 68Ga-DOTA/NOTA-FAPI-04

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 small molecule active

    1 trial

  19. 68Ga-FAPI-04

    The First People's Hospital of Lianyungang

    Liver Fibrosis

    phase 1 small molecule active

    1 trial

  20. 68Ga-FAPI-Biotin

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 small molecule active

    1 trial

  21. 68Ga-JH04

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  22. 68Ga-JH12

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  23. 68Ga-MGS5

    The First People's Hospital of Lianyungang

    Medullary Thyroid Carcinoma

    phase 1 small molecule active

    1 trial

  24. 68Ga-NODAGA-SNA006

    The First People's Hospital of Lianyungang

    Solid Tumor

    phase 1 mab completed

    1 trial

  25. 68Ga-NOTA-MAL-Cys39-exendin-4

    The First People's Hospital of Lianyungang

    Insulinoma

    phase 1 small molecule active

    1 trial

  26. 68Ga-PSMA-11

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  27. 68Ga-Pentixafor

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 1 small molecule active

    1 trial

  28. 99mTc-QULIC-5-P1

    The First People's Hospital of Lianyungang

    Prostate Cancer Stage

    phase 1 small molecule active

    1 trial

  29. A-CAR028

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 1 mab active

    1 trial

  30. AFN50 injection

    The First People's Hospital of Lianyungang

    Autoimmune Diseases

    phase 1 mab active

    1 trial

  31. ATHENA CAR-T

    The First People's Hospital of Lianyungang

    Lupus Erythematosus, Systemic

    phase 1 mab active

    1 trial

  32. Adebrelimab

    The First People's Hospital of Lianyungang

    Biliary Tract Malignancies

    phase 1 small molecule active

    1 trial

  33. Akk Gut Bacteria Supplement

    The First People's Hospital of Lianyungang

    Premature Ovarian Failure (POF)

    phase 1 other active

    1 trial

  34. All-trans retinoic acid

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  35. Amitriptyline Hydrochloride 25Mg Tablet（Hunan DongtingοΌ‰

    The First People's Hospital of Lianyungang

    Depressive Disorder

    phase 1 small molecule completed

    1 trial

  36. Anlotinib hydrochloride,Penpulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  37. Anti-BCMA CAR-T cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  38. Anti-CD19-CAR

    The First People's Hospital of Lianyungang

    Leukemia

    phase 1 mab active

    1 trial

  39. Anti-CD20 monoclonal antibody and the BTK inhibitor

    The First People's Hospital of Lianyungang

    Anti-CD20 Monoclonal Antibody

    phase 1 small molecule active

    1 trial

  40. BAO-G

    The First People's Hospital of Lianyungang

    Thoracoabdominal Aortic Aneurysm

    phase 1 other active

    1 trial

  41. Biological: LV009 injection

    The First People's Hospital of Lianyungang

    CD19+ Relapse/Refractory B-ALL

    phase 1 small molecule active

    1 trial

  42. CAR-BCMA T cells

    The First People's Hospital of Lianyungang

    Refractory or Relapsed Multiple Myeloma

    phase 1 gene therapy active

    1 trial

  43. CAR-T cell infusion

    The First People's Hospital of Lianyungang

    Hematolymphoid Malignancies

    phase 1 small molecule active

    1 trial

  44. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  45. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  46. CBG131 CAR-T Cell Infusion

    The First People's Hospital of Lianyungang

    Advanced Gastric and Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  47. CD19 and BCMA-targeted allogeneic CAR-T cells

    The First People's Hospital of Lianyungang

    Refractory Immune-mediated Platelet Transfusion Refractoriness

    phase 1 gene therapy active

    1 trial

  48. CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing

    The First People's Hospital of Lianyungang

    Refractory Idiopathic Membranous Nephropathy

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.